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Permanent tattoos have become increasingly common, with 
21% of adults in the United States reporting having at least 
one tattoo (1). On rare occasions, outbreaks of nontubercu-
lous mycobacterial (NTM) skin infections have been reported 
after tattooing (2,3). In January 2012, public health officials 
in New York received reports of Mycobacterium chelonae skin 
infections in 14 New York residents who received tattoos dur-
ing September–December 2011. All infections were associated 
with use of the same nationally distributed, prediluted gray ink 
manufactured by company A. CDC disseminated an Epi-X 
public health alert to identify additional tattoo-associated 
NTM skin infections; previously identified cases were reported 
from three states (Washington, Iowa, and Colorado). Public 
health investigations by CDC, state and local health depart-
ments, and the Food and Drug Administration (FDA) found 
NTM contamination in tattoo inks used in two of five identi-
fied clusters. All infected persons were exposed to one of four 
different brands of ink. NTM contamination of inks can 
occur during the manufacturing process as a result of using 
contaminated ingredients or poor manufacturing practices, or 
when inks are diluted with nonsterile water by tattoo artists. No 
specific FDA regulatory requirement explicitly provides that 
tattoo inks must be sterile. However, CDC recommends that 
ink manufacturers ensure ink is sterile and that tattoo artists 
avoid contamination of ink through dilution with nonsterile 
water. Consumers also should be aware of the health risks 
associated with getting an intradermal tattoo. 
On January 4, 2012, the Monroe County (New York) 
Department of Public Health began an outbreak investigation 
after receiving a report of a person with a persistent papular 
rash beginning 1 week after being tattooed by an artist in 
October 2011; M. chelonae was isolated from a skin biopsy. 
Since May 2011, the artist had been using company A predi-
luted gray ink. Using a list of customers provided by the artist, 
a total of 19 infections were identified, including 14 confirmed 
with M. chelonae.
All infected persons had been tattooed with company A 
prediluted gray ink. The tattoo artist said he had not diluted 
the ink before use, and a review of his practices did not reveal 
other potential sources of contamination. M. chelonae was 
isolated from tissue specimens, and from one opened and one 
unopened bottle of company A prediluted gray ink. Pulsed-
field gel electrophoresis (PFGE) patterns of 11 available patient 
isolates and an unopened bottle of company A prediluted gray 
ink were indistinguishable; the M. chelonae isolate from the 
opened ink bottle showed ≥95% genetic relatedness to the 
other isolates. Water and environmental samples collected at 
the manufacturing company and tattoo parlor were negative 
for M. chelonae.
Company A prediluted gray ink was a nationally distributed 
product. To identify additional tattoo-related NTM infections 
not limited to exposure to any particular brand of ink, case 
finding was initiated February 15, 2012, through Epi-X using 
the following case definitions: 1) a possible case was defined 
as persistent inflammatory reaction (i.e., redness, swelling, 
or nodules) localized within the margins of a new tattoo on 
a person between May 1, 2011, and February 10, 2012; 2) a 
probable case was defined as a possible case with evidence of 
an NTM infection by histopathology or clinical response to 
treatment; 3) a confirmed case was defined as a possible case with 
NTM cultured from a wound or skin biopsy. The New York 
cluster included 14 confirmed and four probable cases, and 
one possible case. An investigation by Public Health – Seattle 
& King County, Washington, identified five confirmed and 
26 possible cases. Confirmed cases also were reported from 
Iowa (two) and Colorado (one) (Table). Among 22 confirmed 
cases, 63.6% involved men, and the median age of persons in 
the 22 cases was 33.5 years (range: 20–48 years).
Cases identified in Washington were associated with two 
clusters, and the initial two cases from patients with recent 
tattoos were reported by clinicians to local public health 
authorities. The first, Washington cluster 1, had three con-
firmed Mycobacterium abscessus cases and 24 possible cases in 
persons tattooed with black ink from company B. Water and 
environmental samples collected from company B did not 
grow NTM, but the company reported receiving complaints 
of unusually long-lasting skin reactions in clients tattooed with 
company B black ink from 35 customers in 19 states between 
August 2011 and March 2012. Customer identifiers were 
not available to CDC for follow-up. Two M. abscessus clinical 
isolates from Washington cluster 1 were indistinguishable by 
PFGE, but NTM was not recovered from samples of brand 
B ink. The second Washington cluster had two confirmed 
cases of M. chelonae and two possible cases associated with 
company C gray ink. One clinical isolate from Washington 
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cluster 2 was available for testing. A sample from an opened 
bottle of company C gray ink grew M. chelonae, which was 
unrelated to the Washington cluster 2 clinical isolate and was 
unrelated to New York isolates, based on PFGE patterns. 
Reviews of tattoo practices at the parlors associated with the 
clusters did not reveal other potential sources of contamination.
The Iowa Department of Public Health reported two con-
firmed M. chelonae cases. Patients were tattooed with black 
ink from company C. PFGE testing showed that two clinical 
isolates from Iowa and the clinical isolate from Washington 
cluster 2 were indistinguishable from each other, but unrelated 
to New York isolates. Ink and environmental samples were not 
available for testing.
The Colorado Department of Public Health and Environment 
reported one confirmed case of M. chelonae infection. PFGE 
testing showed that this strain was unrelated to any of the 
clinical and ink isolates identified in other clusters. Artists at 
the Colorado tattoo parlor reported using distilled or reverse 
osmosis water to dilute company D black ink. Although used 
for tattooing, the ink was labeled as a drawing ink, and specified 
as not indicated for tattooing. The artist rinsed needles with 
distilled or reverse osmosis water when switching colors of ink 
on the same client. An unopened bottle of company D black 
drawing ink, reverse osmosis water samples, and environmental 
samples were tested, but NTM were not recovered.
In March and April 2012, FDA conducted inspections 
of company A and company B ink manufacturing sites. 
Ingredients used in the manufacture of tattoo inks at those 
sites included a wide range of pigments, carrier solutions, 
and diluents, including distilled water in some formulations. 
Samples of unopened ink bottles, ink ingredients, environ-
mental samples, distilled water, and tap water were tested at 
CDC and did not yield NTM.
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Editorial Note
This report describes cases of tattoo-associated NTM skin 
infections in four states. The use of ink contaminated before 
distribution or just before tattooing likely led to infections in 
each of the reported clusters. In the New York cluster, NTM 
isolates from clinical specimens, and unopened containers 
of company A prediluted gray ink were indistinguishable. In 
Washington cluster 2 and the Iowa cluster, intrinsic contamina-
tion of company C gray ink was indicated by indistinguishable 
M. chelonae clinical isolates from infected tattoo lesions, with 
no other common exposure except the brand of ink used for 
tattooing. NTM isolates matching cases were not cultured 
from any other brand of ink; however, whether the ink samples 
tested were from the same batches of inks used in the cases 
could not be determined. 
The frequency of NTM skin and soft tissue infections 
occurring subsequent to tattooing is not known, but these 
events have been reported previously, and dilution of inks with 
nonsterile water during tattooing was implicated (3–6). Tattoo-
associated NTM infections can range from mild inflammation 
(e.g., rash, papules, or nodules) to severe abscesses requiring 
TABLE. Characteristics of nontuberculous mycobacteria (NTM) tattoo-associated skin infection clusters — multiple states, 2011–2012
State
No. of cases
Mycobacterium species 
identified
Tattoo ink supplier and type
NoteConfirmed Probable Possible Company Ink
New York 14 4 1 M. chelonae A Prediluted gray Clinical and company A ink isolates 
indistinguishable
Washington 3 0 24 M. abscessus B Black No NTM isolated from company B ink
Washington 2 0 2 M. chelonae C Gray Clinical and company C ink isolates unrelated
Iowa 2 0 0 M. chelonae C Black Available clinical isolates from Iowa cluster and 
Washington cluster 2 were indistinguishable 
Colorado 1 0 0 M. chelonae D Black Clinical isolate was unrelated to New York or 
Washington isolates, no NTM isolated from ink
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extensive and multiple surgical debridements. NTM infections 
are difficult to treat and can require a minimum of 4 months 
of treatment with a combination of two or more antibiotics. 
Physicians who encounter persistent papular rashes or nodules 
localized to newly tattooed areas should consider the possibility 
of an NTM infection. 
Contamination of tattoo inks can occur during the manu-
facturing process and might persist if steps are not taken to 
eliminate harmful microbial contaminants in the finished 
product. A cross-sectional laboratory survey in 2010 of 58 
unopened ink bottles from different manufacturers identified 
intrinsic contamination with a variety of organisms in 10% 
of these inks (7), but did not test for the presence of NTMs. 
Many NTM species (e.g., M. abscessus and M. chelonae) 
are found in water, so the addition of nonsterile water to 
ink during its manufacture or at its point of use could lead 
to contamination with NTM (3–5), and potentially result 
in infections. In addition, a common misconception is that 
distilled and reverse osmosis water are sterile (8), leading to 
the mistaken assumption that these products are acceptable 
for diluting tattoo inks. Dilution of inks with nonsterile water 
or other ingredients at the point of use might lead to product 
contamination. Dilution of ink also will dilute preservatives, 
if present, and make them less effective.
Under the Federal Food, Drug, and Cosmetic Act, tattoo inks 
are considered to be cosmetics, and the pigments used in the 
inks are color additives requiring premarket approval (9). No 
specific FDA regulatory requirement explicitly provides that 
tattoo inks must be sterile. However, intradermal introduction 
of nonsterile substances, such as tattoo ink, can pose a health 
risk and is a public health concern. 
The practice of tattooing may be regulated by local jurisdic-
tions (9). Such regulations generally have required blood-borne 
pathogens training and the use of hygienic practice during tat-
tooing. A few local jurisdictions, such as Los Angeles County 
(10), have issued requirements that sterile water be used in 
tattoo ink dilution. 
The findings in this report are subject to at least the following 
limitation. Because on-site investigations took place months 
after cases were reported, potentially contaminated batches 
and ingredients, such as distilled water and pigments, were 
not available for testing. Similarly, water sources used for the 
manufacture of inks or for ink dilution when patients were 
tattooed were not available. 
Because tattoo inks are injected intradermally, CDC recom-
mends that ink manufacturers be held to higher product safety 
standards, which should include production of sterile inks. 
In addition, tattoo artists should 1) avoid using products not 
intended for use in tattooing; 2) avoid ink dilution before tat-
tooing, and if dilution is needed, use only sterile water; 3) avoid 
use of nonsterile water to rinse equipment (e.g., needles) dur-
ing tattoo placement; and 4) follow aseptic techniques during 
tattooing (e.g., hand hygiene and use of disposable gloves). To 
reduce their risk for infection, consumers should 1) use tattoo 
parlors registered by local jurisdictions; 2) request inks that 
are manufactured specifically for tattoos; 3) ensure that tattoo 
artists follow appropriate hygienic practices; 4) be aware of the 
potential for infection following tattooing, and seek medical 
advice if persistent skin problems occur; and 5) notify the tat-
too artist and FDA’s MedWatch program* if they experience 
an adverse event.
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